Royal Bank of Canada Sells 78,803 Shares of Omnicell, Inc. $OMCL

Royal Bank of Canada decreased its holdings in Omnicell, Inc. (NASDAQ:OMCL) by 12.9% in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 532,172 shares of the company’s stock after selling 78,803 shares during the period. Royal Bank of Canada owned approximately 1.17% of Omnicell worth $17,763,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in OMCL. Wellington Management Group LLP lifted its stake in Omnicell by 156.4% in the fourth quarter. Wellington Management Group LLP now owns 2,075,362 shares of the company’s stock worth $94,014,000 after purchasing an additional 1,265,818 shares during the last quarter. Millennium Management LLC bought a new position in shares of Omnicell during the third quarter valued at about $25,625,000. First Light Asset Management LLC purchased a new position in shares of Omnicell in the first quarter worth about $16,351,000. Boston Partners purchased a new position in shares of Omnicell in the fourth quarter worth about $20,805,000. Finally, WCM Investment Management LLC bought a new stake in shares of Omnicell in the 1st quarter valued at about $9,783,000. Institutional investors own 97.70% of the company’s stock.

Insiders Place Their Bets

In related news, EVP Nnamdi Njoku sold 3,090 shares of Omnicell stock in a transaction on Monday, May 18th. The shares were sold at an average price of $43.22, for a total value of $133,549.80. Following the sale, the executive vice president owned 154,785 shares in the company, valued at $6,689,807.70. The trade was a 1.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Corey J. Manley sold 5,025 shares of the business’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $43.22, for a total transaction of $217,180.50. Following the transaction, the executive vice president directly owned 112,783 shares in the company, valued at approximately $4,874,481.26. The trade was a 4.27% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 2.92% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on OMCL. Wall Street Zen upgraded Omnicell from a “buy” rating to a “strong-buy” rating in a research report on Sunday, May 10th. Wells Fargo & Company lowered their price objective on Omnicell from $55.00 to $50.00 and set an “overweight” rating for the company in a research report on Friday, July 31st. Zacks Research cut shares of Omnicell from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 7th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Omnicell in a research note on Tuesday. Finally, KeyCorp lowered their price target on shares of Omnicell from $70.00 to $65.00 and set an “overweight” rating for the company in a report on Friday, July 31st. Seven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $57.86.

Omnicell Stock Down 2.7%

Shares of NASDAQ:OMCL opened at $36.16 on Friday. The stock’s 50-day moving average is $41.41 and its 200 day moving average is $40.63. The company has a market cap of $1.64 billion, a PE ratio of 43.05, a P/E/G ratio of 1.01 and a beta of 0.98. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.64 and a quick ratio of 1.43. Omnicell, Inc. has a 1 year low of $29.06 and a 1 year high of $55.00.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings data on Thursday, July 30th. The company reported $0.94 earnings per share for the quarter, topping the consensus estimate of $0.47 by $0.47. The business had revenue of $312.21 million during the quarter, compared to analysts’ expectations of $310.21 million. Omnicell had a return on equity of 5.66% and a net margin of 3.13%.The business’s revenue was up 7.4% on a year-over-year basis. During the same quarter last year, the business posted $0.45 EPS. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. Sell-side analysts anticipate that Omnicell, Inc. will post 1.31 EPS for the current year.

Omnicell Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.